Substance use disorders in adolescents with attention deficit hyperactivity disorder: a 4-year follow-up study by Groenman, AP et al.
FOLLOW-UP OF SUBSTANCE USE IN ADHD 
 
1 
 
Substance Use Disorders in Adolescents with Attention Deficit Hyperactivity Disorder: A 
Four-Year Follow-up Study 
Annabeth P. Groenman
1, 2
, Jaap Oosterlaan
1
, Nanda Rommelse
3,4
, Barbara Franke
3,5
, 
Herbert Roeyers
6
, Robert D. Oades
7
, Joseph A. Sergeant
1
, Jan K. Buitelaar
2,4
, Stephen V. 
Faraone
8
 
1 
VU University Amsterdam, Department of Clinical Neuropsychology, Amsterdam, The 
Netherlands;
  
2
Radboud University Nijmegen Medical Centre, Donders Institute for Brain, Cognition and 
Behavior, Department of Cognitive Neuroscience, Nijmegen, The Netherlands; 
3
Radboud University Nijmegen Medical Centre, Donders Institute for Brain, Cognition and 
Behavior, Department of Psychiatry, Nijmegen, The Netherlands; 
4
Karakter Child and Adolescent Psychiatry University Centre, Nijmegen, The Netherlands; 
 
5
Radboud University Nijmegen Medical Centre, Department of Human Genetics, Nijmegen, The 
Netherlands; 
6
 Ghent University, Department of Experimental Clinical Health Psychology, Ghent, Belgium;  
7
 University Clinic for Child and Adolescent Psychiatry, Biopsychology Group, Essen, Germany; 
8
 SUNY Upstate Medical University, Department of Psychiatry and Behavioral Sciences, 
Syracuse, USA. 
 
Number of words: 3483 
 
 
Running Head: FOLLOW-UP OF SUBSTANCE USE IN ADHD 
FOLLOW-UP OF SUBSTANCE USE IN ADHD 
 
2 
 
Correspondence: Dr. Stephen Faraone, Department of Psychiatry and Behavioral Sciences, 
SUNY Upstate Medical University, 750 East Adams St., Syracuse, NY 13210,USA email: 
sfaraone@childpsychresearch.org. Phone: 315-464-3113. Fax: (315) 464-3255  
 
Declaration of interest: 
JO has been on the advisory board of Shire and UCB Pharmaceuticals. He has received an 
unrestricted grant from Shire. HR is a member of an Advisory Board to Shire and has received 
research funding and conference attendance support from Shire and Eli Lilly. RDO has received 
research funding and conference attendance support from Shire. JAS is a member of advisory 
board of Shire en Eli Lilly, has received a research grant from Lilly and speaker fees from Shire, 
Lilly, Janssen-Cillag, Novartis. In the past 3 years, JKB has been a consultant to / member of 
advisory board of / and/or speaker for Janssen Cilag BV, Eli Lilly, Bristol-Myer Squibb, Shering 
Plough, UCB, Shire, Novartis and Servier. He is not an employee of any of these companies, and 
not a stock shareholder of any of these companies. He has no other financial or material support, 
including expert testimony, patents or royalties. In the past year, SVF received consulting 
income and/or research support from Shire, Otsuka and Alcobra and research support from the 
National Institutes of Health (NIH). In previous years, he received consulting fees or was on 
Advisory Boards or participated in continuing medical education programs sponsored by: Shire, 
McNeil, Janssen, Novartis, Pfizer and Eli Lilly. SVF receives royalties from books published by 
Guilford Press: Straight Talk about Your Child’s Mental Health and Oxford University Press: 
Schizophrenia :The Facts. APG, NR, and BF have no conflicts of interest to declare.  
FOLLOW-UP OF SUBSTANCE USE IN ADHD 
 
3 
 
ABSTRACT 
Aim: To examine the relationship between a childhood diagnosis of Attention-
Deficit/Hyperactivity Disorder (ADHD) with or without oppositional defiant disorder 
(ODD)/conduct dicorder (CD) and the development of later alcohol/drug use disorder 
(psychoactive substance use disorder (PSUD)) and nicotine dependence in a large European 
sample of ADHD probands, their siblings and healthy control subjects. 
Participants, Design, Setting: Subjects (n=1017) were participants in the Belgian, 
Dutch and German part of the International Multicenter ADHD Genetics (IMAGE) study. 
IMAGE families were identified through ADHD probands aged 5-1715 years attending 
outpatient clinics, and control subjects from the same geographic areas. After a follow-up period 
(m:4.4 years) this subsample was reassessed at a mean age of 16.4 years.  
Measurements: PSUD and nicotine dependence were assessed using the Diagnostic 
Interview Schedule for Children, Alcohol Use Disorders Identification Test, Drug Abuse 
Screening Test, and Fagerström test for Nicotine Dependence.  
Findings: The ADHD sample was at higher risk of developing PSUD (Hazard Ratio 
(HR)=1.77, 95%CI= 1.05-3.00) and nicotine dependence (HR=8.61, 95%CI=2.44-30.34) than 
healthy controls. The rates of these disorders were highest for ADHD youth who also had CD, 
but could not be accounted for by this comorbidity. We did not find an increased risk of 
developing PSUD (HR=1.18, 95%CI= .62-2.27) or nicotine dependence (HR=1.89, 95%CI=.46-
7.77) among unaffected siblings of ADHD youth.  
Conclusions: A childhood diagnosis of Attention-Deficit/Hyperactivity Disorder is a risk 
factor for psychoactive substance use disorder and nicotine dependence in adolescence, and 
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comorbid Conduct Disorder, but not Oppositional Defiant Disorder, further increases the risk of 
developing psychoactive substance use disorder and nicotine dependence.  
Keywords: Attention-Deficit/Hyperactivity Disorder , Psychoactive Substance Use 
Disorder, Nicotine Dependence, Oppositional Defiant Disorder, Conduct Disorder, familial 
association, age of onset. 
FOLLOW-UP OF SUBSTANCE USE IN ADHD 
 
5 
 
Studies of alcohol abusers report the prevalence of Attention-Deficit/Hyperactivity 
Disorder (ADHD) in this population to range between 35 and 71 percent, while studies of 
substance dependent populations report the prevalence of ADHD to range between 15 and 25 
percent (6). For example, Schubiner et al. (7) found that 24% of 201 adult inpatients in a 
substance abuse treatment facility had ADHD. Levin et al. (8) found that 10% of cocaine 
dependent adults met strict criteria for ADHD. The prevalence rates of ADHD are much 
lower in the general population (e.g. 5.3% in youth (9) and 3 to 5% in adulthood (10-12) 
than in substance dependent subjects.  
Considering the high prevalence of ADHD among substance users, ADHD may be 
more common among adolescents and young adults who later develop psychoactive 
substance use disorder (PSUD; alcohol and/or drug use disorder) than among those who 
will not develop PSUD. This hypothesis is supported by a recent meta-analysis, which showed 
that adolescents with ADHD are at an 1.35 times increased risk of developing an alcohol use 
disorder, an 2.36 times increased risk for nicotine use and an 3.48 times increased risk for non-
alcohol drug use disorder by 3.48 times (for meta-analysis, see 13). Whilst this meta-analysis 
incorporated studies of North American origin, a very large European population-based 
study recently confirmed these results (14), showing that symptoms of ADHD are 
predictive of later substance use.  
Several studies have shown that conduct disorder (CD) and oppositional defiant disorder 
(ODD) play an important role in the later development of PSUD (15-18). For example, August 
et al. (18) showed that only subjects with comorbid externalizing disorders (n = 82) had 
significantly higher rates of PSUD and regular tobacco use compared to both ADHD-only 
(n=27) and healthy control subjects (n=91). While some studies suggest that the increased risk 
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for developing PSUDs that is seen in ADHD could be completely explained by comorbid 
CD/ODD in this group (for a review, see 19), but other studies could not confirm this (16, 20). 
Where these studies underline the importance of examining the relationship between PSUD and 
comorbid CD and ODD in ADHD, most studies used a combined measure of CD and ODD. 
Loeber et al. (21) concluded that CD and ODD are distinct syndromes, which indicates the need 
to consider these two disorders separately. The one study that made this distinction (16) found 
that comorbid CD increased the risk for developing PSUD, while ADHD comorbidity with ODD 
did not. This issue therefore deserves further investigation. 
 Family studies of ADHD document an association between ADHD and PSUD in the 
family members of children with ADHD. Higher rates of alcoholism were found in the adult 
siblings of adult ADHD probands compared to the siblings of psychiatric controls (22). Similar 
findings have been obtained in two large double-blind family-genetic studies of female and male 
ADHD probands (23-24), in which higher rates of PSUD in the relatives of ADHD probands 
were reported compared to relatives of comparison subjects without ADHD. Taken together, 
these findings suggest that ADHD and PSUD may share familial causes. All these studies, 
however, included relatives of ADHD probands, regardless of their ADHD status, making it 
difficult to disentangle common environmental effects from the effects of ADHD. 
This study describes a four-year follow-up of a large sample of Western European 
origin of well-defined childhood diagnosed probands with ADHD and both their affected and 
unaffected siblings. This study uses multiple informants for ADHD, PSUD, and nicotine 
dependence diagnoses. The aim of the present study was to assess (1) the prevalence and age of 
onset of PSUD in a large sample of ADHD probands followed up in early to late adolescence (2) 
the effects of an additional childhood diagnosis of ADHD-comorbid ODD or CD on developing 
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PSUD in ADHD probands, and (3) the familial risk of PSUD in unaffected siblings of ADHD 
probands.  
FOLLOW-UP OF SUBSTANCE USE IN ADHD 
 
8 
 
Method 
Subjects  
Subjects participating in this study were part of the Belgian, Dutch and German 
International Multicenter ADHD Genetics (IMAGE) study (2). IMAGE families were identified 
through ADHD probands ages 5 to 17 years attending outpatient clinics at the data collection 
sites between 2003 and 2006. For each ADHD proband, at least one available sibling was 
recruited. Siblings were not required to have ADHD, but a diagnosis of ADHD was not used as 
an exclusion criteria. Family members were European Caucasian descent. Exclusion criteria 
applying to both probands and siblings included autism, epilepsy, IQ < 70, brain disorders and 
any genetic or medical disorder associated with externalizing behaviors that might mimic 
ADHD. Additional healthy control-participants were recruited from primary and high schools 
from the same geographical regions as the participating ADHD-families.  
Probands, siblings and healthy control subjects were assessed at baseline and re-invited to 
participate in a follow-up study on average 4.4 years (SD=.71) after study entry. A total of 1,017 
(85.3 % of original sample) children and adolescents above the age of 12 participated in the 
follow-up (also see Table 1). A total of 63 participants participated at the Belgian site, 36 at the 
German site, and 915 at the Dutch site. At baseline, no significant differences between those 
successfully followed-up and those lost to follow-up on age and gender (all p values >.05). 
At baseline, no differences were found among ADHD participants followed-up and those 
lost to follow-up on ADHD severity, CD and ODD (all p values >.05). Ethical approval for the 
study was obtained from the National Institute of Health registered ethical review boards for 
each center. After a complete description of the study, written informed consent was obtained 
from parents and children.  
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ADHD, ODD and CD diagnoses 
In ADHD families both probands and siblings were screened similarly, using the standard 
procedures of the IMAGE project described fully elsewhere (2). Briefly, baseline measures 
included the Long Version of Conners’ Parent (CPRS-R:L), and Teacher Rating Scale (CTRS-
R:L; 3), used to identify and quantify ADHD symptoms. T-scores ≥ 63 on the Conners ADHD 
subscales (L, M and N) were considered clinical. Healthy control subjects were required to not 
have a clinical score on these measures. A full description of measures used and the 
algorithm used is provided in Box 1.   
Follow-up Measures 
A parental report of PSUD was obtained using the SUD module of the Diagnostic 
Interview Schedule for Children (DISC-IV-P; 25). The DISC-IV-P was administered by 
telephone, and scored with a computer-algorithm to derive DSM-IV-defined SUD diagnoses. 
Age of first substance use was also assessed in the interview. A number of questionnaires was 
completes by participants. The Alcohol Use Disorders Identification Test (AUDIT; 26) was used 
to identify self-reported alcohol dependence. Scores on the AUDIT may range from 0-40. A 
score of 9 or higher was used to define alcohol abuse, and a score of 13 or more in girls and 15 
or more in boys was used as a cut-off to define alcohol dependence (26). The Drug Abuse 
Screening Test–20 (DAST; 27) was used to assess drug use disorders. Scores on this 
questionnaire may range from 0–20. A cut-off of 5 was used to identify possible drug use 
disorders (27). The Fagerström test for Nicotine Dependence (FTND; 28) was used to assess 
nicotine dependence. Scores on this questionnaire may vary between 0 and 10. A cut-off of 6 
was used to identify nicotine dependence (28). Age of first nicotine use was also assessed in this 
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questionnaire. All participants were provided with a personal return envelope to increase trust, 
and ensure confidentiality of sensitive information. 
A best-estimate diagnosis of PSUD was considered present if either alcohol or drug 
use disorder was present in the subject. A best-estimate diagnosis of alcohol use disorder 
was considered present if either scores on the AUDIT (self-report) or DISC-IV-P alcohol 
module (parent-report) met criteria stated above. A best-estimate diagnosis of drug use 
disorder was considered present if either the DAST (self-report) or DISC-IV-P marihuana 
module or other drugs module (parent-report) met criteria stated above. Nicotine 
dependence was considered present if scores on either the FTND (self-report) or the 
tobacco module of the DISC-IV-P (parent report) met criteria stated above.  
Statistical analyses 
All analyses were conducted using SPSS 18.0 (SPSS Inc., Chicago, IL, USA). In the 
present analysis, probands with ADHD as well as affected siblings were included in the ADHD 
group. Three groups were used in the analyses: subjects diagnosed with ADHD at baseline, their 
unaffected siblings and healthy control subjects. ANOVAs were performed to assess whether 
groups differed on IQ at baseline, age at follow-up, follow-up interval, and t-scores on the 
oppositional scales of the CTRS:R-L. A Kruskal-Wallis test assessed whether groups differed in 
the proportion of males.  
To investigate whether the risk of developing PSUD and nicotine dependence differed 
between the groups Cox Proportional-hazard models were fitted. Correction for clustered 
(family) data was done using robust standard errors (29). The models used age of first substance 
use as the survival time for the cases and current age as the time of censoring for the non-cases.  
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When an increased risk of developing PSUD or nicotine dependence was observed, we 
explored whether this was related to ADHD, ODD or CD, using Cox Proportional-hazard 
models. The effects of ODD and CD were analyzed separately. To assess the effect of childhood 
ODD and CD on the risk of developing PSUD, the sample was divided into 4 groups: healthy 
controls, ADHD subjects without ODD or CD (the ADHD-only group), ADHD subjects with 
ODD and ADHD subjects with CD. Of 47 of the 511 ADHD-subjects, data were missing 
regarding the presence of absence of ODD/CD and consequently these cases were left out of 
the analyses.  
Linear regression models were fitted using General Estimation Equations (GEE; 30) to 
assess the effects of a childhood diagnosis of ADHD, ODD or CD on age of first substance use. 
GEE is a method that takes into account clustered data in family studies. Correction for family 
dependency was done using family number as repeated measure.  
We used the Holm sequential Bonferroni-method  (31) to correct for multiple testing. 
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Box1. Detailed description of IMAGE diagnostic measures and algorithm 
Baseline measures included the Parental Account of Childhood Symptoms (PACS; 1) interview. The PACS 
is a semi-structured, standardized, investigator-based interview developed to provide an objective measure of 
child behavior. A trained interviewer administered the PACS to parents, who were asked for detailed 
descriptions of their child’s typical behavior in a range of specified situations (for an exact description of the 
interview procedure, we refer to 2). These included the Long Version of Conners’ Parent (CPRS-R:L), and 
Teacher Rating Scale (CTRS-R:L; 3). A standardized algorithm was applied to the PACS to derive each of 
the 18 DSM-IV ADHD-symptoms, providing operational definitions for each behavioral symptom. These 
were combined with items that were scored 2 (pretty much true) or 3 (very much true) in the teacher-rated 
Conners ADHD subscales (L, M, and N) to generate the total number of hyperactive-impulsive and 
inattentive symptoms of the DSM-IV symptom list (4). A standardized algorithm was applied to combine 
symptom count on the PACS and CTRS-R:L, both providing operational definitions of each of the 18 
behavioral symptoms defined by the DSM-IV. Situational pervasiveness was defined as symptoms occurred 
within two or more different situations as assessed with the PACS interview, as well as the presence of one 
or more items scored 2 or higher or more from the ADHD scale of the CTRS-R:L (for a full description of 
the algorithm procedure also see,5). The PACS sections dealing with disruptive behavior (ODD and CD) are 
structured similarly to the ADHD section, except that symptoms are not evaluated across multiple situations. 
The PACS assesses all DSM-IV (4) ODD and CD symptoms. Symptom ratings were dichotomized with 
absence of a symptom coded as 0 and presence of symptom as 1, and then summed separately for ODD and 
CD symptoms. Two categorical measures of disruptive behavior encompassing ODD and CD were defined. 
The first measure defined ODD according to the DSM-IV criteria based on information from the PACS and 
the CPRS-R:L. The second measure defined CD according to the DSM-IV criteria using a standardized 
algorithm applied to the PACS. Subjects with ODD were not allowed to score positive for CD, while subjects 
with CD were allowed to score positive for ODD. In addition to the interview, rating scales were used to 
quantify ADHD and ODD severity. 
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Results 
Demographics 
Table 1 describes demographic and clinical features of the three groups (top panel; 
ADHD (n=511), unaffected siblings (n = 286) and healthy control subjects (n= 220)). At 
baseline, 176 of the ADHD subjects met criteria for ODD and 91 subjects met criteria for CD. 
Four unaffected siblings were diagnosed with having ODD, none had CD. None of the healthy 
control subjects met criteria for ODD or CD. There were small but statistically significant group 
differences in current age, follow-up interval, gender and IQ. The lower panel of Table 1 
displays the demographic and clinical features of the ADHD-only, ADHD+ODD, ADHD+CD 
and healthy control group. These groups did not differ in current age, however significant group 
differences were found in follow-up interval, IQ, ODD severity, and gender. All subsequent 
analyses were statistically adjusted for current age, gender and follow-up interval. 
 
-Insert Table 1 about here- 
 
Risk for PSUD and Nicotine Dependence in ADHD 
Adolescents with a childhood ADHD diagnosis were 1.8 times more likely to develop an 
PSUD 8.6 times more likely to develop nicotine dependence compared to healthy controls. 
Interestingly, unaffected siblings were not at increased risk of developing an PSUD or nicotine 
dependence compared to healthy controls. Unaffected siblings were 2.9 times less likely to 
develop nicotine dependence compared to their ADHD siblings, while they did not differ in the 
risk to develop an PSUD (also see Table 2). 
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-Insert Table 2 about here- 
 
Risk for PSUD and Nicotine Dependence in ODD and CD 
An increased risk of developing an PSUD was found for the group with comorbid 
ADHD+ CD (HR=2.45, 95%CI=1.17-5.19) and for the ADHD-only group (HR=2.02, 
95%CI=1.07-3.83) compared to healthy controls. Interestingly, the comorbid ADHD+ODD 
group was not at increased risk of developing an PSUD compared to healthy control subjects 
(HR=1.07, 95%CI=.50-2.28). Compared to the ADHD-only group, the comorbid ADHD+CD 
group was not at increased risk of developing PSUD (HR=1.20, 95%CI=.78-2.07), while the 
comorbid ADHD+ODD group was at decreased risk of developing an PSUD (HR=.53, 
95%CI=.311-.91) however this did not remain significant after correction for multiple 
comparisons(see left panel Figure 1).  
 
-Insert Figure 1 about here- 
 
The risk for developing nicotine dependence was increased in the comorbid ADHD+CD 
group (HR=13.96, 95%CI=2.89-67.49), the comorbid ADHD+ODD group (HR=8.36, 
95%CI=1.78-39.30) and the ADHD-only group compared to healthy controls (HR=6.58, 
95%CI=1.50-28.96). The comorbid ADHD+ODD group did not have an increased risk for 
developing nicotine dependence compared to the ADHD-only group (HR=1.33, 95%CI=.68-
2.62), while the comorbid ADHD+CD group did have an increased risk (HR=2.22, 
95%CI=1.09-4.53) (see right panel Figure 1).  
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All analyses were re-run with the ADHD-only group and healthy controls to check 
whether increased levels of ODD severity in the ADHD-only group are at the base of the 
increased risk for PSUD and nicotine dependence that was found. After correction for ODD 
severity the ADHD-only group remained at increased risk of developing nicotine dependence 
(HR=6.64, 95%CI=1.40-31.425), however, not for developing an PSUD (HR=1.67, 
95%CI=.83-3.35). 
Age of onset 
Participants with a childhood ADHD diagnosis had a younger age of first substance use 
(B=-.525, Waldχ2=7.035, p=.008) and nicotine use (B=-1.631, Waldχ2=36.768, p<.001) 
compared to healthy controls. Unaffected siblings were younger at commencement of nicotine 
use (B=-.762, Waldχ2=6.940, p=.008) compared to healthy controls, but not in terms of age of 
first substance use (B=.158, Waldχ2=.949, p=.330).  
Analyses that focused on the effect of ODD and CD on the age of first substance use, 
revealed that younger age of first use was found for the comorbid ADHD+CD (B=-.905, 
Waldχ2=10.551, p=.001) and the ADHD-only group (B=-1.398, Waldχ2=17.453, p<.001) 
compared to healthy controls. The finding of a younger age of first substance use in the 
comorbid ADHD+ODD group did not survive correction for multiple comparisons 
(uncorrected:B=-.473, Waldχ2=4.584, p=.032). The ADHD+ODD and ADHD+CD groups did 
not have a younger age of first substance use compared to the ADHD-only group (B=.165, 
Waldχ2=.630, p=.427 and B=-.432, Waldχ2=2.994, p=.084, respectively).  
Analyses focusing on the effect of ODD and CD for the age of first nicotine use revealed 
a younger age of first use in the comorbid ADHD+CD group (B=-2.147, Waldχ2=29.786, 
p<.001), the comorbid ADHD+ODD group (B=-1.398, Waldχ2=17.453, p<.001) and the 
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ADHD-only group (B=-1.767, Waldχ2=22.785, p<.001) compared to healthy controls. 
Compared to the ADHD-only group, age of first nicotine use was not different in the comorbid 
ADHD+CD, and the comorbid ADHD+ODD group (B=-.380, Waldχ2=.887, p=.346 and 
B=.368, Waldχ2=1.100, p=.294, respectively).  
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Discussion 
This four year follow-up study of ADHD adolescents confirms prior reports indicating 
that childhood ADHD is a risk factor for the subsequent development of PSUD and nicotine 
dependence (13, 32). At a mean age of around 16 years, our ADHD sample compared with 
healthy controls showed a higher prevalence of PSUD as well as nicotine dependence. We did 
not find an increased risk for unaffected siblings of developing PSUD or nicotine dependence. 
Our results do not confirm prior studies suggesting that the increased risk of developing nicotine 
dependence, which is seen in ADHD, could completely be accounted for by comorbid CD (33). 
Interestingly, we observed that subjects with comorbid ADHD+ODD did not demonstrate an 
increased risk for developing PSUD or nicotine dependence compared to healthy controls, while 
the ADHD-only group did. The risk of developing either PSUD or nicotine dependence were 
largest for the comorbid ADHD+CD group. 
Several studies have shown that youth who smoke cigarettes have an increased risk 
for alcohol and drug use disorders (34). The high risk of smoking among ADHD youth 
suggests that our sample is at high risk for future alcohol and drug use disorders. In one 
study (35), cigarette smokers were more likely to subsequently use illegal drugs compared 
with non-smokers. Another study reported that smoking a pack of cigarettes per day 
increased the risk for illicit drug use ten to thirty times (36). A recent study found similar 
results in subjects with ADHD (37). This suggests that nicotine use can be seen as a 
gateway to other drugs in typically developing children and in subjects with ADHD. 
The existing literature is inconsistent concerning the role of CD in later development 
of PSUD in adolescents with ADHD. While some studies yielding supportive evidence (e.g., 
18), most fail to demonstrate that ADHD without comorbid CD does not increase risk for 
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the development of PSUD and nicotine dependence (e.g., 16). Our results confirm the latter 
studies in that, in the absence of CD, youth with ADHD are still at increased risk of PSUD 
and nicotine dependence compared to healthy control subjects. However, the increased risk 
for developing PSUD in the ADHD-only group compared to the healthy control group, 
disappeared after correction for ODD severity. In the current study, we demonstrate that 
subjects with a childhood diagnosis of ADHD with comorbid CD are at much higher risk of 
developing PSUD and nicotine dependence compared to ADHD subjects without CD. We 
replicate the findings of Biederman et al. (16) that CD is a risk factor for the development of 
PSUD in ADHD, although this risk is not observed here for ODD. While ADHD subjects with 
ODD were at increased risk for developing nicotine dependence compared to healthy control 
subjects, their risk was not increased compared to the ADHD-only subjects. Although ODD is a 
risk factor for developing CD, some evidence suggests that CD is more likely to persist into 
adolescence than ODD (10.8% vs. 32.5%; (38). Possibly, only a current ODD/CD diagnosis 
is a risk factor for PSUD. Unfortunately, to our knowledge, no studies have examined the effect 
of persistence of ODD or CD on the later development of PSUD. Consistent with previous 
research (17, 39), we showed that subjects with ADHD and ADHD+CD have an earlier age of 
first substance use. To our knowledge, this is the first study to show that subjects with a childhood 
ADHD+ODD diagnosis do not start at a younger age using substances compared to healthy 
control subjects.  
Prior family studies of ADHD have shown that ADHD and PSUD co-aggregate in 
families (40-42). In contrast to these findings, we did not find an increased prevalence of PSUD 
and nicotine dependence among the unaffected siblings of our ADHD probands. The failure to 
find support for this hypothesis cannot be attributed to a lack of power, because we had a fairly 
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large sample of unaffected siblings (N=286). The lack of difference may be explained by the 
selection procedure that was used for unaffected siblings, as prior studies assessed the prevalence 
of PSUD in siblings regardless of the presence or absence of ADHD (43). Importantly, this could 
indicate that ADHD itself, and not shared family environment, are responsible for the increased 
risk of adolescents with ADHD to develop PSUD or nicotine dependence. However, another 
possible reason for the failure to replicate elevated risk for siblings is their main age around 17 
years, which could mean that many participants in our study did not pass the ages of highest risk 
for substance use disorders. Indeed, despite the lack of statistically significant differences, it is 
notable that for all comparisons (Table 2), the hazard ratios comparing siblings to healthy 
controls were greater than 1.0. Future studies should follow-up subjects with childhood 
diagnosed ADHD at later ages to elucidate this important issue. 
Our results should be considered in the context of some methodological limitations. Our 
sample only included Caucasian youth. Because our ADHD probands were referred for ADHD, 
and at initial inclusion of the study all had combined type ADHD,  we cannot generalize our 
findings to community samples of adolescents with ADHD. However, our results – which are 
mainly based on participants with combined subtype ADHD, show striking resemblance to 
the results found in community based samples – which typically include more subjects with 
inattentive type of ADHD (e.g.,18). A possible explanation is that symptoms of inattention 
are predictive of later PSUD (17, 44-45). Furthermore, the current ADHD sample had a 
much larger proportion of males than the unaffected siblings and healthy control subjects. 
Although we corrected for gender, the gender composition of our sample might have 
affected the results. Parent report of age of first psychoactive substance use was used in our 
analyses, possibly causing an overestimation of age of first substance use. However, a 
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reporting bias between parents of ADHD subjects and controls seems unlikely, it is not 
expected that this has affected our results. Finally, we used adult cut-off scores for the self-
report questionnaires. Although this approach would not have biased results to finding 
spurious case-control differences, it may have influenced our estimates of prevalence. 
Despite these limitations, we add to current knowledge on three levels. First, we have 
provided further evidence that ADHD is a risk factor for PSUD and nicotine dependence, and 
that ADHD accelerates the onset of these disorders. Furthermore, we found that ADHD with 
comorbid CD, but not ODD, further increases the risk of developing PSUD, but subjects with 
ADHD without comorbidities are still at increased risk. No evidence was found that this 
increased risk of developing PSUD and nicotine dependence in participants with ADHD is 
due to familial risk factors shared by the unaffected siblings, i.e. genes and/or the common 
environment.  
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Table 1. Subject characteristics. 
 ADHD 
n=511 
Unaffected 
Siblings 
n=286 
Healthy 
Controls 
n= 220 
 
 
 
 
 m SD m SD m SD  F p  
Age (min-max) 16.4 
(12.0-
22.6) 
2.4 16.9 
(12.1-
24.4) 
3.3 
 
16.4 
(12.2-
23.2) 
2.5  3.4 .033 U>A=HC 
% Male 80.0 - 45.1 - 40.5 -  149.8
a 
<.001
 
A>U=HC 
Estimated Full-scale IQ  100.0 14.1 102.8 13.5 105.6 9.5  13.7 <.001 A<U=HC 
Follow-up Interval in Years 4.58 .56 4.54 .49 3.71 .78  173.96 <.001 HC<A=U 
ADHD Diagnosis at Baseline           
- Inattentive 44  - - - -     
- Hyperactive/Impulsive 18  - - - -     
- Combined 446  - - - -     
 ADHD 
-only 
n= 197 
ADHD 
-ODD 
n= 176 
ADHD 
-CD 
n= 91 
Healthy 
Controls  
n= 220 
   
 m  SD m SD m SD m SD F p  
Age  
(range) 
16.55 
(12.1-
22.6) 
2.50 16.49 
(12-
22.3) 
2.35 16.46 
(12.1-
22.5) 
2.56 16.36 
(12.2-
23.2) 
2.52 .245 .865 A=O=CD=HC 
% Male 75.6 - 83.0 - 89.0 - 40.0 - 120.76
a 
<.001 HC<A=O>CD 
Estimated Full-scale IQ 101.33 14.15 98.73 14.50 99.13 12.32 105.58 9.49 10.69 <.001 A=O=CD<HC 
Follow-up Interval in Years 4.64 .54 4.59 .53 4.53 .59 3.71 .78 97.81 <.001 A=O<CD<C 
T-score Oppositional Scale  
CTRS:R-L at Baseline 
60.56 13.11 61.68 13.30 66.90 13.64 48.72 6.66 73.036 <.001 HC<A=O<CD 
Note: Group comparisons were done using Tukey when variances were equal, otherwise Dunnett’s T3 was used; A=ADHD group, U=Unaffected siblings, 
HC=Healthy controls, O=oppositional defiant disorder, CD= conduct disorder. 
aχ2. 
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Table 2. Prevalence rates of substance use disorder and nicotine dependence in adolescents with ADHD, their unaffected siblings and 
healthy controls  
 Prevalence Rates  Hazard Ratios 
 ADHD 
n=511 
 Unaffected 
Siblings 
n=286 
 Healthy 
Controls 
n= 220 
 ADHD  
vs. 
Healthy Controls 
 Unaffected 
Siblings  
vs. 
ADHD 
 Unaffected 
Siblings 
vs. 
Healthy 
Controls 
 n %  n %  n %  HR 95% CI  HR 95% CI  HR 95% CI 
Psychoactive Substance 
Use Disorder  
103 20.2  41 14.4  26 11.8  1.77* 1.05-3.00  .76 .51-1.15  1.18 .62-2.27 
Nicotine Dependence 50 9.8  12 4.2  6 2.7  8.61* 2.44-30.34  .35* .16-.76  1.89 .46-7.77 
Note: Hazard Ratios were calculated using Cox proportional hazard regression. All comparisons were corrected for gender and follow-up interval in years. HR: 
Hazard ratios. 95% CI= 95% confidence interval.  
* Significant at p<.05. 
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Figure 1: Cumulative Lifetime Risk for any Psychoactive Substance Use Disorder and Nicotine Dependence  
  
Note: All comparisons were corrected for gender and follow-up interval. Unaffected siblings were left out of analyses because only 4 subjects met criteria for 
ODD.  
 
 
 
